Jeena Sikho Lifecare Limited ($JSLL)

Ladies and gentlemen, good day, and welcome to Jeena Sikho Lifecare Limited Q4 and FY '26 Earnings Call hosted by Go India Advisors. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Ms. [indiscernible] from Go India Advisors. Thank you, and over to you, ma'am.

Good day, everyone, and welcome to Q4 and FY '26 Conference Call of Jeena Sikho Lifecare Limited. We have on call with us Mr. Manish Grover, the Managing Director; Mr. Nanak Chand, the Chief Financial Officer. We must remind you that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks pertaining to the business. I now request the management to take us through the business update. And post that, we'll open the floor for Q&A. Thank you, and over to you, sir.

[Foreign Language]

Yes. Good afternoon, everyone. I will now take you through the key financial highlights for Q4 FY '26 prepared in accordance with the [ Ind AS]. So [indiscernible] has delivered a robust financial performance for quarter and year ending 31st of March 2026. For quarter, our revenue from the operations stood INR 216 crores, up by 55% year-to-year. Gross profit increased to INR 191 crores with gross margin of 88%. Our EBITDA came in INR 78 crores recording 70% year-on-year growth with margin at 36%. Profit after tax stood at INR 45 crores, reflecting a 79% year-on-year growth. Our basic EPS for the quarter is INR 3.65. Similarly, our FY '26 covered revenue from the operations stood at INR 801 crores, up by 71%. Gross profit grew by 71% to INR 710 crores. This gross margin, our EBITDA came in INR 349 crores by 149% -- by growing 149%, while EBITDA margin grew by booking 1,360 basis points to 44%. Our PAT also adjusted as a robust growth of 177% to rate [indiscernible] crores PAT margin registering a growth of 1,062 VPS to 28%. The improvement in profitability was driven by the higher operating leverage from the increased patient volumes, strong contribution from the higher margin of the product and sales, controlled operating expense despite of our network expansion. Our balance sheet remains strong with prudent financial management, improving cash flow and capital-light expansion strategy supporting the superior ROCE. However, in Q4, our Q-on-Q basis, there is a short-term impact onetime nonrecurring items largely on the account of higher provisioning relating to the new labor ESOP provisioning and certain performance-linked bonus approximately INR 7 crores. For further clarity on this during the quarter, we made a onetime ECL provision approximately INR 5 crores. [indiscernible] The appointment of a new statutory auditor and adoption of the applicable accounting treatment under the Ind AS, the company conducted the review of the lease adjustment. A part of this review, certain additional provision was booked for the lease related expenses, approximately INR 9 crores, which impacted the profit for the quarter incremental provision for approximately INR 1.25 crores related to loyalty points accrued under the company health card program. I would like to clarify that Q4 earnings decline is solely due to these onetime items and does not reflect any weakness in the business. Excluding these operations remain stable, the company stayed committed to sustainable growth.

[Operator Instructions] We will take our next question from the line of [indiscernible].

[Foreign Language] First of all, congratulations on a good set of numbers.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Operator Instructions] We will take our next question from the line of [ Ankur ] from Genuity Capital.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of [ Ankur Kumar ] from [indiscernible] Capital.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of [indiscernible].

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Operator Instructions] Next question is from the line of Deepak Poddar from [ Sapphire ] Capital.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of Naveen Baid from [indiscernible].

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of [ Hitesh Jain ] from [indiscernible] Capital. As there is no response from the current participant, we will take the next question from [indiscernible].

[Foreign Language] Congratulations on the Q4 results.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of Hitesh Jain from Avagrah Capital.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of from Abhishek from AB Capital.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of Praveen Kumar from Praveen Investment.

[Foreign Language]

[Foreign Language]

Sir, my first comment is that you guys device so many medicines and I kindly request you to device medicine for investors not to panic when the stock falls. And coming to my question, sir, you said there is a great momentum on the ground.

[Foreign Language]

Sir, I'm not that comfortable, sir. I'm sorry, I'm really not that comfortable. My first question is, you said there is a great momentum on the ground now. So what can we expect for FY '27? What can be the revenue guidance, you want to say anything on that? That's my first question.

[Foreign Language]

Understood. And my second question, sir, you want to give any latest status on your engagement with [indiscernible]. Any latest data you want to share with investors? And are they really helping us in moving our business? Anything on that you would like to share, sir, with investors.

[Foreign Language]

[Operator Instructions] We will take our next question from the line of next question is from Deepak...

[Foreign Language]

All right, sir, noted. So the next question is from the line of [indiscernible].

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of Priyanshu Jain from Growth X Infinity.

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

[Foreign Language]

Next question is from the line of Priyam from [indiscernible].

[Foreign Language]

[Foreign Language]

Thank you, sir. Ladies and gentlemen, we will take that as the last question for today. Kindly share your queries on [indiscernible], and we apologize that we couldn't take all due to time constraints. I now hand the conference over to the management for closing remarks.

[Foreign Language]

Thank you very much. On behalf of Go India Advisors, that concludes this conference. Thank you all for joining us today, and you may now disconnect your lines.